VERA — Vera Therapeutics, Inc. stock price, charts and financials

Latest market price

29.95

-2.28-7.07%

Overview Short InterestFilings

VERAQT30Vera Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

29.95-7.07%

Earnings

Down 7.1% — Reported earnings — EPS missed by 27%.

High confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PVLA+7.96%$151.99 SLS+5.26%$11.81 ZLAB+1.71%$18.49 BHVN+2.84%$13.75 NUVB+4.55%$6.44 ADMA+1.95%$8.91 HRMY+8.93%$38.78 SION+1.38%$49.94

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	71.78M	Perf Week	-10.11%

Market Cap	2.15B	Forward P/E	-	EPS next Y	-3.91	Insider Trans	-0.39%	Shs Float	58.51M	Perf Month	-25.37%

Enterprise Value	1.63B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	25.78%	Perf Quarter	-15.66%

Income	-300.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	9.54	Perf Half Y	-33.86%

Sales	0.00	P/B	4.30	EPS next Y	36.78%	ROA	-59.34%	Short Interest	15.08M	Perf YTD	-40.86%

Book/sh	6.97	P/C	3.60	EPS next 5Y	-	ROE	-74.86%	52W High	56.05 -46.57%	Perf Year	42.96%

Cash/sh	8.32	P/FCF	-	EPS past 3/5Y	-	ROIC	-66.50%	52W Low	19.07 57.05%	Perf 3Y	74.13%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.39% 5.65%	Perf 5Y	69.88%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-101.45%	Oper. Margin	0.00%	ATR (14)	2.11	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	13.64	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	26.26	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	13.64	EPS Q/Q	-108.64%	SMA20	-19.27%	Beta	0.86	Target Price	87.14

Payout	0.00%	Debt/Eq	0.13	Sales Q/Q	-	SMA50	-18.23%	Rel Volume	2.91	Prev Close	32.23

Employees	249	LT Debt/Eq	0.13	Earnings	Aug 05	SMA200	-23.08%	Avg Volume	1.77M	Price	29.95

IPO Date	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.22% -	Net Debt/EBITDA	0.11	Volume	5,136,414	Change	-7.07%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-08-26	Reiterated	Needham
Jul-08-26	Reiterated	HC Wainwright & Co.	Buy	$90
Jul-08-26	Reiterated	Wedbush	Neutral	$33 → $43
Jul-08-26	Reiterated	Guggenheim	Buy	$76
Jun-02-26	Reiterated	Jefferies	Buy	$6.00 → $60
Jun-02-26	Reiterated	Goldman Sachs	Buy	$95 → $90
May-15-26	Reiterated	Evercore ISI Group	Outperform	$97 → $91
Mar-11-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Dec-19-25	Reiterated	Goldman Sachs	Buy	$95
Dec-11-25	Reiterated	Wedbush	Neutral	$34 → $33

Latest News

Jul-11-26

Jul-11-2602:02PM

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launchmarketbeat.com

Jul-10-26

Jul-10-2604:05PM

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

11:14AM

Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunYahoo

Jul-09-26

Jul-09-2608:00AM

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turnerglobenewswire.com

Jul-07-26

Jul-07-2607:12PM

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy TranscriptSeekingAlpha

12:42PM

US FDA approves Vera's kidney disease drugreuters.com

12:37PM

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathyglobenewswire.com

Jul-06-26

Jul-06-2611:39AM

What's Going on with Vera Therapeutics Stock on Monday?benzinga.com

Jun-23-26

Jun-23-2602:50PM

Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New OpportunitiesSeekingAlpha

Company

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	-1	0	0	1
Gross Profit	0	0	0	1	0	0	-1
Selling, General and Administrative Excl. Other	100	41	24	22	12	4	4
Research and Development	215	126	78	70	22	44	7
Other Operating Expense	0	0	0	0	0	0	1
Operating Income	-315	-167	-102	-91	-34	-48	-12
Interest Expense	8	8	4	1	0	0	0
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	23	23	10	3	2	-5	0
Net Income Before Taxes	-300	-152	-96	-89	-33	-53	-12
Income Taxes	0	0	0	0	0	0	0
Consolidated Net Income	-300	-152	-96	-89	-33	-53	-12
Net Income From Continuing Operations	-300	-152	-96	-89	-33	-53	-12
Net Income	-300	-152	-96	-89	-33	-53	-12
EPS (Recurring)	-4.66	-2.75	-2.25	-3.35	-2.43	-14.40	-3.46
EPS (Basic, Before Extraordinaries)	-4.66	-2.75	-2.25	-3.35	-2.43	-14.40	-3.46
EPS (Diluted)	-4.66	-2.75	-2.25	-3.35	-2.43	-14.40	-3.46
EBITDA	-292	-144	-92	-89	-32	-53	-11
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	64	55	43	27	13	4	3
Market Capitalization	3,241	2,326	661	522	347	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fordyce Marshall	PRESIDENT AND CEO	Jul 07 '26	Sale	42.30	46,250	1,956,187	151,994	Jul 09
Fordyce Marshall	PRESIDENT AND CEO	Jun 23 '26	Sale	37.93	18,500	701,769	198,244	Jun 24
Fordyce Marshall	PRESIDENT AND CEO	May 12 '26	Sale	36.74	18,500	679,747	216,744	May 13
Fordyce Marshall	PRESIDENT AND CEO	Apr 14 '26	Sale	44.05	22,951	1,011,051	235,244	Apr 15
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Mar 13 '26	Option Exercise	3.94	10,000	39,396	75,754	Mar 16
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Feb 23 '26	Sale	41.98	3,117	130,864	64,722	Feb 25
Brenner Robert	Chief Medical Officer	Feb 23 '26	Sale	41.98	2,151	90,307	50,947	Feb 25
Grant Sean	CHIEF FINANCIAL OFFICER	Feb 23 '26	Sale	41.98	4,949	207,778	114,181	Feb 25
Fordyce Marshall	PRESIDENT AND CEO	Feb 23 '26	Sale	41.98	16,925	710,578	257,163	Feb 25
JOHNSON DAVID LEE	Chief Operating Officer	Feb 23 '26	Sale	41.98	2,579	108,276	45,727	Feb 25
Turner William D.	Chief Regulatory Officer	Feb 23 '26	Sale	41.98	2,187	91,819	45,313	Feb 25
Skelton Laurence Matthew	Chief Commercial Officer	Feb 23 '26	Sale	41.98	1,582	66,419	64,218	Feb 25
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.